Values First Advisors Inc. Takes $457,000 Position in Beta Bionics, Inc. (NASDAQ:BBNX)

Values First Advisors Inc. bought a new stake in Beta Bionics, Inc. (NASDAQ:BBNX - Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 37,585 shares of the company's stock, valued at approximately $457,000. Values First Advisors Inc. owned approximately 0.09% of Beta Bionics as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Rhumbline Advisers bought a new position in shares of Beta Bionics in the first quarter valued at approximately $158,000. Bank of New York Mellon Corp bought a new position in shares of Beta Bionics in the first quarter valued at approximately $316,000. Finally, Evanson Asset Management LLC bought a new position in shares of Beta Bionics in the first quarter valued at approximately $475,000.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on BBNX shares. The Goldman Sachs Group initiated coverage on Beta Bionics in a report on Friday, May 30th. They issued a "neutral" rating and a $16.00 target price on the stock. Lake Street Capital started coverage on Beta Bionics in a research report on Thursday, June 12th. They issued a "buy" rating and a $30.00 price objective on the stock. Wolfe Research started coverage on Beta Bionics in a research report on Friday, May 30th. They issued an "outperform" rating and a $20.00 price objective on the stock. Finally, Truist Financial started coverage on Beta Bionics in a research report on Monday, June 16th. They issued a "buy" rating and a $26.00 price objective on the stock. Four investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Beta Bionics currently has a consensus rating of "Moderate Buy" and an average price target of $23.44.

Beta Bionics Stock Performance

BBNX stock opened at $13.40 on Tuesday. The stock has a fifty day simple moving average of $15.48. Beta Bionics, Inc. has a 1-year low of $8.89 and a 1-year high of $24.50.

Beta Bionics (NASDAQ:BBNX - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.01).

Insider Activity

In other Beta Bionics news, CFO Stephen Feider sold 1,497 shares of the business's stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $17.89, for a total value of $26,781.33. Following the sale, the chief financial officer directly owned 45,503 shares in the company, valued at $814,048.67. The trade was a 3.19% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders sold 4,519 shares of company stock valued at $80,845 in the last 90 days.

Beta Bionics Company Profile

Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.